Home
This site is intended for healthcare professionals

Primary Care Obesity Roadmap Australia: Module 2 Initiation of Management at Point of Eligibility

Share

Description

This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally, excluding the UK.

Join leading expert Dr Ralph Audehm for this accredited virtual session exploring the practical initiation of obesity management at the point of clinical eligibility. Through interactive polling questions and a case-based patient journey, this module examines how to assess obesity severity and related complications, individualize treatment decisions, and integrate lifestyle intervention, pharmacotherapy, and specialist care into a structured, patient-centered management plan.

Participants will gain practical strategies for moving beyond BMI alone, setting meaningful treatment goals, selecting appropriate anti-obesity therapies, and monitoring treatment response while preserving physical function and lean mass.

Session Highlights

  • Recognizing the Right Time to Initiate Treatment: Explore how obesity severity, complications, risk factors, and patient goals can inform timely initiation of active obesity management.
  • Individualizing Pharmacological Treatment: Learn how to select and monitor anti-obesity medications based on treatment eligibility, clinical response, comorbidities, patient preferences, and access considerations.
  • Integrating Lifestyle, Pharmacotherapy, and Specialist Care: Understand how structured lifestyle interventions, pharmacotherapy, and metabolic or bariatric surgery can be combined within a personalized, multidisciplinary care pathway.
  • Monitoring Outcomes Beyond Weight Loss: Discover practical approaches to tracking treatment response, physical function, body composition, and cardiometabolic risk while supporting the preservation of lean mass and long-term health.

This is Module Two of Four. Modules One, Three and Four can be found here.

Prefer to read? see our Key Clinical Summary Here

Who Should Watch

This activity is intended for primary care providers, nurse practitioners, physician assistants/associates, pharmacists, and other healthcare providers who care for patients with obesity.

Faculty

Dr Ralph Audehm is a general practitioner who graduated from Melbourne University in 1984 and has worked for over 25 years in general practice. He is experienced in managing all types of patients. He obtained a Diploma from the Royal Australian College of Obstetricians and Gynaecologists in 1987 and is an Honorary Clinical Associate Professor at the Department of General Practice, University of Melbourne. He has had a long-standing interest in the management of chronic conditions in General Practice especially diabetes and heart disease.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Ralph Audehm, faculty for this educational activity, has the following relevant financial relationships: Advisory Board and Consultant for AstraZeneca, Boehringer Ingelheim, Lilly and NovoNordisk.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate Continuing Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number -JA4008073-9999-26-293-H01-P

Type of Activity: Knowledge

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information

There is no fee for this educational activity.

This continuing education activity is active starting September 10th 2026, and will expire on August 4th 2027.

Estimated time to complete this activity: 15 Minutes

Learning objectives

  1. Employ bias-aware communication and structured shared decision making (SDM) at the point of diagnosis, utilizing the patient's specific metabolic and mechanical complications to collaboratively set function-based goals for people with obesity, demonstrating correct application in > 75% of post-activity case assessments.

  2. Initiate guideline-concordant treatment plans – integrating pharmacotherapy, structured lifestyle interventions, and surgical referrals – while implementing workflows to monitor physical function and preserve body composition, achieving appropriate treatment decisions in > 75% of simulation scenarios.

  3. Apply structured reassessment algorithms to determine treatment efficacy, true therapeutic non-response amid weight plateaus, and timely treatment escalations in > 70% of longitudinal case exercises.

  4. Formulate proactive long-term adherence pathways — including proactive side-effect mitigation, the timely review of concomitant medications, and a patient-centered review of therapeutic options in > 75% of applied decision activities.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

So Here's another poll for you. Um, when do you typically initiate obesity treatment? When the patient asks for help. When BMI reaches a treatment threshold. When complications or risk markers are present, after lifestyle only attempts have been unsuccessful, or do you usually refer to a specialist to manage this? And let me say I have been guilty of the top 4, so certainly when patients ask for help, that's um an easy end to supporting people. BMI of course we now know is not the best way, but certainly BMI is something that I always keep an eye on, and of course when people start getting obesity related diseases or complications, and of course people who have tried really hard um and then were unsuccessful. So, our 51 year old lady has come back. Her BMI is 34, um, and she's got a waist circumference of 104, so she certainly has clinical obesity. Her BP remains above target and she also has pre-diabetes. Her knee pain continues. And you know, it's obviously an issue for her walking up and down stairs as well as walking outside. She's tried diet apps um with short-term weight loss but nothing that's lasting. I really do go into quite a lot of detail about what diets people have been on and which ones were successful and which ones weren't and, you know, what happened, um how long were you, were you able to maintain that, because it gives me a, a real sense of where they are on their journey. And of course, ah a very, very relevant question, what else can I do that will actually last, which is of course something that we all grapple with even with our medications. So, you know, when we manage or looking at someone who's got clinical obesity, we always do a full physical, we look at the weight distribution or you know, the, the, the, the, the, the pattern of, of fat, like, you know, going, where is it, is it around the waist, um, the previous weight loss attempts, always being careful around eating habits, um, you know, some people with obesity will have eating disorders and we do need to be aware of that. Sleep and stress plays a big role, and I'm always ah reminded by that ah um the ah, The place in America where they've actually got a, a list to register a list of all people who've lost weight greater than 10% and kept it off, and one of the big things they did was stress management, um, which I thought was really important. Um, and of course doing our lab assessments and LA's of course um has been found to have pre-diabetes, and then, you know, talk about where we're gonna go. What are the goals and this is something, I must admit I, I. I've, I've learned how to do a little bit better because often my treatment goals were very different to their treatment goals, and trying to align the two together is really key because you need to keep them on the journey with you and, you know, it's, it's their goals that will give them that motivation and enable them, you know, to, to take, to keep on that journey, um, as especially as they start to see things improve. So, We really want to individualize a care plan, we want to stage the severity, we want to individualize the therapy and get appropriate treatment goals that are basically, you know, between the two of us, cause I do like to also put in some of my treatment goals at the same time, and then we decide between us which way we're going to go. And so er lifestyle, um, I know we often give it a bit of lip service, but this is critical for all patients, um even if they're on some of our anti-obesity agents, um because we know lifestyle's critical for adequate nutrition but also maintaining muscle mass. Whether they do that through individual or group-based, I must admit I'm a bit of a fan of the group-based um interventions. Um, physical activity is critical, um, and it, it, you know, in Australia we'll use either physiotherapist or exercise physiologist, and they will actually do the prescription of the activity and the exercise, and they'll really make it appropriate for that person. And of course we're talking about initially a reduced calorie diet. Um, and that of course has to be culturally appropriate in Australia, that's, um, uh, we see this every day because we're, we're such a multicultural, um, country. And then, you know, then we look at um the anti-obesity medications, you know, um, And the indication here is very much in Australia though if you have a BMI greater than 30 or a BMI greater than 27, um, with some sort of complications, and of course, you know, there are a group of people who'll have BMI's less than 27 but have excess adiposity, um, and we need to be really aware of those as well. But you know, we need to, um, Also look for things that patients maybe on, um, that are causing weight gain and again ah for me the biggest one's always been the antipsychotics, some of them we won't be able to change because sometimes people are on clozapine because they are really difficult to treat and so then it becomes managing the impact of that, um, Monitoring, um, and look, every 3 months, I, I would say that's as a minimum, I tend to, especially in the beginning, monitor them far more frequently, because it is a chronic condition, and we'd also want to look out for any of the side effects that will, um, you know, stop people participating or if there's been a hiccup that's stopped them from doing some of their lifestyle. Um So And But I mean this is, you know, one algorithm sort of, you know, where your goal 5 to 10%, start off with, you know, lifestyle and if you're going to use some of the uh anti-obesity medications, um, we don't have the combination of phen um phentermine and topiramate here but certainly I have used topiramate in the past, um, and of course, you know, it's something that we became aware of when people had uh migraine. Again, we don't have the um, Ah, we do have naltrexone bupropion, um, again, modest, ah, weight loss, but, um, many people, you know, if they want to have a greater weight loss, we're certainly are spoilt by the impacts of the GLP ones and the GIP GLP ones, and, um, but there are nuances around that and I actually like this slide, so this is from the European. Um, group, and they've got this nice little algorithm about looking at adipocity and where the evidence sits, um, onto what you should be using. And I think it's a great little diagram, not that, you know, we will probably think that many of the other agents will work there, but this is where the solid evidence exists, so if you want to have an evidence-based approach to what you're doing, um, you can use this, so, for our lady, if um, you know, she ended up having, you know, moderate to severe sleep apnea, um you can see that under the, Mechanical adipocity issues, obstructive sleep apnea, you can use, I mean there's great evidence around tazepetide, so you can see how each of these works so with diabetes, of course we've got quite a few, pre-diabetes and so on. We shouldn't forget about metabolic and bariatric surgery, I mean access to it in Australia's, um, quite problematic, um, but it's certainly very, very effective, and, you know, we'll give them a sustained weight loss for many years, and of course for people who have a BMI greater than 40, it's probably the better choice, but again, I have seen what I term as super responders ah to some of the, Your agents, um, and so I'll always go down the path of using medication first, but again it's a shared decision with the person in front of you, um, and, you know, you're giving them a choice and then they can do, you know, what's right for them at that point in time once they've had all the information. One of the key points though, If you go down the metabolic surgery, um, long-term, ah, review is critical, ah, because they do get micronutrient deficiencies, so we need to screen them at least annually, um, because, ah, you know, they're, they're, they're at risk of significant, significant, um, ah, micronutrient deficiencies and macros as well, so. So You know, again, as I said before, we need to monitor our patients closely.